What is it about?

In the study it is shown that the Access testosterone assay showed no interference by the Abiraterone, a drug with steroidal structure used in castration-resistant prostate cancer.

Featured Image

Read the Original

This page is a summary of: Evaluation of the possible interference of abiraterone therapy on testosterone immunoassay, Clinical Chemistry and Laboratory Medicine (CCLM), March 2019, De Gruyter,
DOI: 10.1515/cclm-2018-1288.
You can read the full text:

Read

Contributors

The following have contributed to this page